{"id":42531,"date":"2022-04-01T07:28:24","date_gmt":"2022-04-01T07:28:24","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=42531"},"modified":"2022-04-01T20:57:00","modified_gmt":"2022-04-01T20:57:00","slug":"phase-1-hiv-vaccine-study-launched-using-mrna-technology","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/42531","title":{"rendered":"HIV vaccine study using mRNA technology starts in the US"},"content":{"rendered":"
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

The rapid development of vaccines against COVID-19 led many people to question whether similar investment could have achieved an effective HIV vaccine.<\/b><\/p>\n<\/div>\n

\n

One response emphasised that decades of HIV research were actually enabling faster treatments for COVID-19. Another reported that mRNA technology behind the Pfizer and Moderna vaccines might now be transferrable back to efforts against HIV.<\/span><\/p>\n<\/div>\n

\n

On 14 March 2022, the US NIH issued a press statement about the launch of a phase 1 study of three experimental HIV vaccine based on mRNA technology. [1]<\/span><\/p>\n<\/div>\n

\n

The HVTN 302 study will look at safety and immune responses in up to 108 adult participants in ten US cities. The three candidate vaccines are: (i) BG505 MD39.3 mRNA, (ii) BG505 MD39.3 gp151 mRNA, and (iii) BG505 MD39.3 gp151 CD4KO mRNA.\u00a0<\/span><\/p>\n<\/div>\n

\n

This research programme was first announced by Moderna in January 2021. [2]<\/span><\/p>\n<\/div>\n

\n

References<\/span><\/p>\n<\/div>\n

\n
    \n
  1. NIH launches clinical trial of three mRNA HIV vaccines: phase 1 study is among first to examine mRNA technology for HIV. (14 March 2022).
    \n<\/span>https:\/\/www.nih.gov\/news-events\/news-releases\/nih-launches-clinical-trial-three-mrna-hiv-vaccines<\/a><\/li>\n
  2. Moderna PR. <\/span>Moderna provides business update and announces three new development programs in infectious disease vaccines. (11 January 2021).
    \n    https:\/\/investors.modernatx.com\/news\/news-details\/2021\/Moderna-Provides-Business-Update-and-Announces-Three-New-Development-Programs-in-Infectious-Disease-Vaccines-01-11-2021\/default.aspx<\/a><\/li>\n<\/ol>\n

    This report was first published on 16 March 2022.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base The rapid development of vaccines against COVID-19 led many people to question whether similar investment could have achieved an effective HIV vaccine. One response emphasised that decades of HIV research were actually enabling faster treatments for …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-42531","post","type-post","status-publish","format-standard","hentry","category-transmission-and-prevention"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=42531"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/42531\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=42531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=42531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=42531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}